2seventy bio

The company is led by Nick Leschly, 2seventy bio's chief kairos officer, and former chief bluebird.

In March 2022, 2seventy bio secured $170 million in a private placement, following which Mr Leschly said: "We have increasing conviction in the Abecma [idecabtagene vicleucel; ide-cel] US commercial launch, we are executing on a plan to rebalance our burn, and we have secured important funding from leading healthcare investors. Taken together, we expect these steps will get us through critical milestones and into 2025."

Latest 2seventy bio News & Features